Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy ATAI Life Sciences stock

Learn how to easily invest in ATAI Life Sciences stock.

Atai Life Sciences, a Peter Thiel-backed company that produces psychedelic and non-psychedelic mushroom-based therapies for depression and anxiety, is expected to go public. We'll update this page as new information emerges.

How to buy ATAI Life Sciences stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – ATAI. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award

eToro


  • Easy to use platform with $0 stock trading & no annual fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100

Promoted for options trading

tastytrade


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+

ATAI Life Sciences stock price (NASDAQ: ATAI)

Use our graph to track the performance of ATAI stocks over time.

ATAI Life Sciences shares at a glance

Information last updated 2023-03-16.
Latest market close$1.22
52-week range$1.14 - $5.74
50-day moving average $1.78
200-day moving average $3.12
Wall St. target price$13.55
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.29

Buy ATAI Life Sciences stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 7 of 7
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
eToro
Stocks, Options, ETFs, Cryptocurrency
$0
$0
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
tastytrade
Stocks, Options, ETFs, Cryptocurrency, Futures
$0
$0
Get $100 - $2,000
when you you open and fund an account with $5,000 to $100,000+
Highly commended for Best Derivatives Trading Platform award.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives, Treasury Bills
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Diversify your portfolio by trading stocks, ETFs, T-Bills, crypto, rare collectibles and more.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs, Treasury Bills
$0
$0
Get $50 - $700
when you open and fund an account with $10,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
E*TRADE
Stocks, Bonds, Options, Mutual funds, ETFs, Futures
$0
$0
Get up to $600 or more
when you open and fund a new account.
E*TRADE offers commission-free stocks, access to mutual funds and advanced trading tools. Other fees apply.
loading

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy ATAI Life Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ATAI Life Sciences price performance over time

Historical closes compared with the close of $1.22 from 2023-03-17

1 week (2023-03-09) N/A
1 month (2023-02-16) -32.60%
3 months (2022-12-20) -59.06%
6 months (2022-09-20) -66.76%
1 year (2022-03-18) -78.41%
2 years (2021-03-16) N/A
3 years (2020-03-16) N/A
5 years (2018-03-16) N/A

ATAI Life Sciences financials

Revenue TTM $425,000
Gross profit TTM $20.4 million
Return on assets TTM -22%
Return on equity TTM -53.78%
Profit margin 0%
Book value $1.75
Market capitalisation $207.3 million

TTM: trailing 12 months

ATAI Life Sciences share dividends

We're not expecting ATAI Life Sciences to pay a dividend over the next 12 months.

ATAI Life Sciences overview

Atai Life Sciences N. V. , through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.

Frequently asked questions

What percentage of ATAI Life Sciences is owned by insiders or institutions?
Currently 9.275% of ATAI Life Sciences shares are held by insiders and 34.869% by institutions.
How many people work for ATAI Life Sciences?
Latest data suggests 87 work at ATAI Life Sciences.
When does the fiscal year end for ATAI Life Sciences?
ATAI Life Sciences's fiscal year ends in December.
Where is ATAI Life Sciences based?
ATAI Life Sciences's address is: Krausenstrasse 9-10, Berlin, Germany, 10117
What is ATAI Life Sciences's ISIN number?
ATAI Life Sciences's international securities identification number is: NL0015000DX5

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site